Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/1/2025

Long-Term Home Oxygen Therapy in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Indications for Home Oxygen Therapy

  • The European Respiratory Society recommends long-term home oxygen therapy (LTOT) in patients with COPD who have severe hypoxemia at rest (PaO2 ≤7.3 kPa or ≤55 mmHg) or moderate hypoxemia (PaO2 ≤8 kPa or ≤60 mmHg) with evidence of peripheral edema, polycythemia, or pulmonary hypertension 1
  • Patients with stable COPD and a PaO2 at rest ≤7.3 kPa (55 mmHg) should receive LTOT, as it offers survival benefits and improves pulmonary hemodynamics, according to the European Respiratory Society and Thorax 1, 2
  • LTOT should also be prescribed to patients with stable COPD and a PaO2 ≤8 kPa (60 mmHg) who have peripheral edema, polycythemia (hematocrit ≥55%), or pulmonary hypertension, as recommended by the European Respiratory Society and Thorax 1, 3

Benefits of Home Oxygen Therapy

  • LTOT has been shown to increase survival in patients with COPD and chronic respiratory failure, with a strength of evidence rated as high by the European Respiratory Journal 2
  • LTOT improves pulmonary hemodynamics and reduces the progression of pulmonary hypertension, according to Thorax 1
  • Administering oxygen for 15 or more hours daily to maintain a PaO2 above 60 mmHg reduces mortality in patients with severe COPD, as demonstrated by the Annals of Internal Medicine 4

Administration Modalities

  • Nasal cannulas should be considered as the first option for home oxygen administration, as recommended by Thorax 5
  • Oxygen concentrators are recommended for administering LTOT at flow rates of 4 L/min or less, according to Thorax 5
  • Venturi masks may be considered in patients with concerns about existing or developing hypercapnic respiratory failure, as suggested by Thorax 5

Patient Follow-up and Education

  • Patients starting LTOT should receive formal education from a specialized team in home oxygen assessment to ensure treatment adherence, as recommended by Thorax 6
  • Follow-up should be performed 3 months after prescribing LTOT, including arterial blood gas evaluation and flow adjustment to ensure that LTOT remains necessary and therapeutic, according to Thorax 6

Special Situations

  • Nocturnal oxygen therapy is not recommended in patients with COPD who have nocturnal hypoxemia but do not meet the criteria for LTOT, as stated by Thorax 6
  • Palliative oxygen therapy should not be administered to patients with cancer or cardiopulmonary disease in the terminal phase who experience intractable dyspnea if they are not hypoxemic or have mild hypoxemia above the current LTOT thresholds (SpO2 ≥92%), according to Thorax 5

Warnings and Precautions

  • LTOT is generally not prescribed to patients who continue smoking due to safety risks, as noted by the European Respiratory Journal 2, 3
  • Patients with cognitive, visual, or coordination impairment may not be able to safely manipulate their own oxygen flows and should be maintained on a single flow, as recommended by Thorax 6